Kurt B. Stevenson, MD, MPH
Professor, Internal Medicine
Associate Director of Clinical Epidemiology
N1122 Doan Hall
410 W. 10th Avenue
Columbus, Ohio 43210
Dr. Stevenson is a tenured Professor of Internal Medicine and Epidemiology in the Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, and the Division of Epidemiology, College of Public Health. He is also the Associate Medical Director of Clinical Epidemiology for the OSU Health System where he serves as the Director of the Antimicrobial Stewardship Program. He joined the OSU faculty in 2005
Dr Stevenson’s clinical interests focus on antimicrobial resistance in the healthcare setting and healthcare-associated infections (HAIs). One major area of research emphasis is examining strategies to optimize the utilization of antimicrobial agents to prevent the development and spread of resistance. He also focuses on understanding the development of HAIs and examining infection control interventions to limit their occurrence and impact. A third area of emphasis is in utilizing electronic health data for the surveillance and detection of HAIs. These research interests include diverse healthcare settings beyond OSU including those with limited resources such as rural hospitals and long-term care facilities. To support these research endeavors, he was from 2006-2011 the Principal Investigator of one of five Center for Disease Control and Prevention (CDC)-funded Prevention Epicenters (http://www.cdc.gov/ncpdcid/).
More broadly, Dr. Stevenson is interested in applying the principles of healthcare epidemiology to improving many aspects of clinical care. He is a fellow of the Society for Healthcare Epidemiology of America, and a member of the Infectious Diseases Society of America, American College of Physicians, and the Association for Professionals in Infection Control and Epidemiology. He recently completed a five year term as a member the CDC’s Healthcare Infection Control Practices Advisory Committee (HICPAC). He was recently appointed to the FDA Anti-Infective Drug Advisory Committee.